Automate Your Wheel Strategy on ANGO
With Tiblio's Option Bot, you can configure your own wheel strategy including ANGO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ANGO
- Rev/Share 6.9351
- Book/Share 4.5497
- PB 2.0177
- Debt/Equity 0.0269
- CurrentRatio 2.2094
- ROIC -0.1179
- MktCap 372772260.0
- FreeCF/Share -0.8128
- PFCF -11.2261
- PE -9.0605
- Debt/Assets 0.0175
- DivYield 0
- ROE -0.2137
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving patient quality of life, today announced the first patient has been enrolled in the RECOVER-AV clinical trial, a prospective, multi-center, multi-national, single-arm study evaluating the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System in t.
Read More
Zacks Industry Outlook Penumbra, Integer and AngioDynamics
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Negative
Zacks names PEN, ITGR and ANGO as medical device stocks riding genAI advances, despite global and inflationary headwinds.
Read More
3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
PEN, ITGR and ANGO from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and supply issues mar prospects.
Read More
What Makes AngioDynamics (ANGO) a Strong Momentum Stock: Buy Now?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Does AngioDynamics (ANGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Are Medical Stocks Lagging AngioDynamics (ANGO) This Year?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how AngioDynamics (ANGO) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.
Read More
Wall Street Analysts See a 63.23% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 63.2% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year?
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how AngioDynamics (ANGO) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Read More
Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 68.28%: Read This Before Placing a Bet
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 68.3% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
ANGO reports solid fiscal third-quarter earnings with continued strength in its Med Tech segment. The expansion of gross margin bodes well.
Read More
Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance
Published: April 02, 2025 by: Benzinga
Sentiment: Positive
AngioDynamics Inc. (NASDAQ: ANGO) on Wednesday reported a third-quarter 2025 adjusted EPS of 3 cents, compared to the consensus for a per-share loss of 13 cents.
Read More
About AngioDynamics, Inc. (ANGO)
- IPO Date 2004-06-01
- Website https://www.angiodynamics.com
- Industry Medical - Instruments & Supplies
- CEO James C. Clemmer
- Employees 748